CN104661681B - 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合 - Google Patents

包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合 Download PDF

Info

Publication number
CN104661681B
CN104661681B CN201380049140.1A CN201380049140A CN104661681B CN 104661681 B CN104661681 B CN 104661681B CN 201380049140 A CN201380049140 A CN 201380049140A CN 104661681 B CN104661681 B CN 104661681B
Authority
CN
China
Prior art keywords
compound
cancer
combination
alkyl
aromatase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380049140.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104661681A (zh
Inventor
M·戈登布伦纳
X·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104661681A publication Critical patent/CN104661681A/zh
Application granted granted Critical
Publication of CN104661681B publication Critical patent/CN104661681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380049140.1A 2012-09-20 2013-09-18 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合 Active CN104661681B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261703533P 2012-09-20 2012-09-20
US61/703,533 2012-09-20
US201261708070P 2012-10-01 2012-10-01
US61/708,070 2012-10-01
PCT/US2013/060292 WO2014047109A1 (en) 2012-09-20 2013-09-18 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor

Publications (2)

Publication Number Publication Date
CN104661681A CN104661681A (zh) 2015-05-27
CN104661681B true CN104661681B (zh) 2018-07-03

Family

ID=49263471

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380049140.1A Active CN104661681B (zh) 2012-09-20 2013-09-18 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合

Country Status (21)

Country Link
US (1) US9532982B2 (enExample)
EP (1) EP2897644B1 (enExample)
JP (1) JP6212563B2 (enExample)
KR (1) KR102220965B1 (enExample)
CN (1) CN104661681B (enExample)
AU (1) AU2013318205B2 (enExample)
BR (1) BR112015004152A2 (enExample)
CA (1) CA2880506C (enExample)
CY (1) CY1120984T1 (enExample)
DK (1) DK2897644T3 (enExample)
ES (1) ES2686689T3 (enExample)
HR (1) HRP20181413T1 (enExample)
HU (1) HUE040520T2 (enExample)
IN (1) IN2015DN00735A (enExample)
LT (1) LT2897644T (enExample)
MX (1) MX356278B (enExample)
PL (1) PL2897644T3 (enExample)
PT (1) PT2897644T (enExample)
RU (1) RU2651023C2 (enExample)
SI (1) SI2897644T1 (enExample)
WO (1) WO2014047109A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948351C (en) * 2014-05-09 2023-10-03 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors
CN118593514B (zh) * 2024-05-09 2025-05-27 西南医科大学附属医院 芳香化酶抑制剂在制备治疗黑色素瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149711A (zh) * 2008-09-10 2011-08-10 诺瓦提斯公司 有机化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506563A (ja) * 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
WO2009080694A1 (en) * 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
EP2311842A3 (en) * 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149711A (zh) * 2008-09-10 2011-08-10 诺瓦提斯公司 有机化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
抗癌药物磷脂酰肌醇3激酶抑制剂;王宇驰等;《国外医药抗生素分册》;20081231;第29卷(第5期);206-212页 *
芳香化酶抑制剂的研究进展;崔中立等;《中国药物化学杂志》;20100228;第20卷(第1期);70-76页 *

Also Published As

Publication number Publication date
KR20150056778A (ko) 2015-05-27
CA2880506C (en) 2021-04-20
CA2880506A1 (en) 2014-03-27
MX356278B (es) 2018-05-22
HUE040520T2 (hu) 2019-03-28
WO2014047109A1 (en) 2014-03-27
IN2015DN00735A (enExample) 2015-07-10
HRP20181413T1 (hr) 2018-10-19
BR112015004152A2 (pt) 2017-07-04
MX2015003657A (es) 2015-06-05
US20150231124A1 (en) 2015-08-20
US9532982B2 (en) 2017-01-03
DK2897644T3 (en) 2018-09-10
AU2013318205B2 (en) 2016-05-19
RU2015111171A (ru) 2016-11-10
JP2015532927A (ja) 2015-11-16
EP2897644B1 (en) 2018-06-06
CY1120984T1 (el) 2019-12-11
ES2686689T3 (es) 2018-10-19
EP2897644A1 (en) 2015-07-29
SI2897644T1 (sl) 2018-10-30
LT2897644T (lt) 2018-09-25
RU2651023C2 (ru) 2018-04-18
PL2897644T3 (pl) 2018-11-30
JP6212563B2 (ja) 2017-10-11
KR102220965B1 (ko) 2021-02-26
CN104661681A (zh) 2015-05-27
PT2897644T (pt) 2018-10-16
AU2013318205A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
KR102318306B1 (ko) 암의 치료를 위한 조합 요법
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
US20160199365A1 (en) 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases
CN105338980A (zh) 药物组合
EP2750675A1 (en) Synergistic combinations of pi3k- and mek-inhibitors
CN104661681B (zh) 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合
US20180318275A1 (en) Combination therapy using pi3k inhibitor and mdm2 inhibitor
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
US20180256557A1 (en) Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant